Abstract

The pandemic of coronavirus disease 2019 (COVID-19) caused by the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has affected more than 10 million people, including pregnant women. To date, no consistent evidence for the vertical transmission of SARS-CoV-2 exists. The novel coronavirus canonically utilizes the angiotensin-converting enzyme 2 (ACE2) receptor and the serine protease TMPRSS2 for cell entry. Herein, building upon our previous single-cell study (Pique-Regi, 2019), another study, and new single-cell/nuclei RNA-sequencing data, we investigated the expression of ACE2 and TMPRSS2 throughout pregnancy in the placenta as well as in third-trimester chorioamniotic membranes. We report that co-transcription of ACE2 and TMPRSS2 is negligible in the placenta, thus not a likely path of vertical transmission for SARS-CoV-2. By contrast, receptors for Zika virus and cytomegalovirus, which cause congenital infections, are highly expressed by placental cell types. These data show that the placenta minimally expresses the canonical cell-entry mediators for SARS-CoV-2.

Data availability

Placenta and decidua scRNA-seq data from first-trimester samples were downloaded through ArrayExpress (E-MTAB-6701). Data for third-trimester samples previously collected by our group are available through NIH dbGAP (accession number phs001886.v1.p1), and newly generated second-trimester scRNA-seq and third-trimester snRNA-seq data are being deposited in the same repository.

The following data sets were generated
The following previously published data sets were used

Article and author information

Author details

  1. Roger Pique-Regi

    Center for Molecular Medicine and Genetics, Wayne State University, Detroit, United States
    For correspondence
    rpique@wayne.edu
    Competing interests
    The authors declare that no competing interests exist.
    ORCID icon "This ORCID iD identifies the author of this article:" 0000-0002-1262-2275
  2. Roberto Romero

    Center for Molecular Medicine and Genetics, Wayne State University, Detroit, United States
    For correspondence
    prbchiefstaff@med.wayne.edu
    Competing interests
    The authors declare that no competing interests exist.
    ORCID icon "This ORCID iD identifies the author of this article:" 0000-0002-4448-5121
  3. Adi L Tarca

    Department of Obstetrics and Gynecology, Wayne State University, Detroit, United States
    Competing interests
    The authors declare that no competing interests exist.
    ORCID icon "This ORCID iD identifies the author of this article:" 0000-0003-1712-7588
  4. Francesca Luca

    Center for Molecular Medicine and Genetics, Wayne State University, Detroit, United States
    Competing interests
    The authors declare that no competing interests exist.
    ORCID icon "This ORCID iD identifies the author of this article:" 0000-0001-8252-9052
  5. Yi Xu

    Department of Obstetrics and Gynecology, Wayne State University, Detroit, United States
    Competing interests
    The authors declare that no competing interests exist.
  6. Adnan Alazizi

    Department of Obstetrics and Gynecology, Wayne State University, Detroit, United States
    Competing interests
    The authors declare that no competing interests exist.
  7. Yaozhu Leng

    Department of Obstetrics and Gynecology, Wayne State University, Detroit, United States
    Competing interests
    The authors declare that no competing interests exist.
  8. Chaur-Dong Hsu

    Department of Obstetrics and Gynecology, Wayne State University, Detroit, United States
    Competing interests
    The authors declare that no competing interests exist.
  9. Nardhy Gomez-Lopez

    Department of Obstetrics and Gynecology, Wayne State University, Detroit, United States
    For correspondence
    ngomezlo@med.wayne.edu
    Competing interests
    The authors declare that no competing interests exist.
    ORCID icon "This ORCID iD identifies the author of this article:" 0000-0002-3406-5262

Funding

National Institutes of Health (HHSN275201300006C)

  • Roberto Romero

Wayne State University (Perinatal Initiative)

  • Adi L Tarca
  • Nardhy Gomez-Lopez

The funders had no role in study design, data collection and interpretation, or the decision to submit the work for publication.

Reviewing Editor

  1. Stephen CJ Parker, University of Michigan, United States

Ethics

Human subjects: The collection and use of human materials for research purposes were approved by the Institutional Review Board of the Wayne State University School of Medicine [IRB# 110605MP2F(RCR), IRB# 082403MP2F(5R), and IRB# 031318MP2F]. All participating women provided written informed consent prior to sample collection.

Version history

  1. Received: May 13, 2020
  2. Accepted: July 6, 2020
  3. Accepted Manuscript published: July 14, 2020 (version 1)
  4. Version of Record published: July 17, 2020 (version 2)
  5. Version of Record updated: July 17, 2020 (version 3)

Copyright

This is an open-access article, free of all copyright, and may be freely reproduced, distributed, transmitted, modified, built upon, or otherwise used by anyone for any lawful purpose. The work is made available under the Creative Commons CC0 public domain dedication.

Metrics

  • 6,907
    views
  • 947
    downloads
  • 204
    citations

Views, downloads and citations are aggregated across all versions of this paper published by eLife.

Download links

A two-part list of links to download the article, or parts of the article, in various formats.

Downloads (link to download the article as PDF)

Open citations (links to open the citations from this article in various online reference manager services)

Cite this article (links to download the citations from this article in formats compatible with various reference manager tools)

  1. Roger Pique-Regi
  2. Roberto Romero
  3. Adi L Tarca
  4. Francesca Luca
  5. Yi Xu
  6. Adnan Alazizi
  7. Yaozhu Leng
  8. Chaur-Dong Hsu
  9. Nardhy Gomez-Lopez
(2020)
Does the human placenta express the canonical cell entry mediators for SARS-CoV-2?
eLife 9:e58716.
https://doi.org/10.7554/eLife.58716

Share this article

https://doi.org/10.7554/eLife.58716

Further reading

    1. Epidemiology and Global Health
    2. Medicine
    3. Microbiology and Infectious Disease
    Edited by Diane M Harper et al.
    Collection

    eLife has published the following articles on SARS-CoV-2 and COVID-19.

    1. Genetics and Genomics
    Mohammad Alfatah, Jolyn Jia Jia Lim ... Frank Eisenhaber
    Research Article

    Uncovering the regulators of cellular aging will unravel the complexity of aging biology and identify potential therapeutic interventions to delay the onset and progress of chronic, aging-related diseases. In this work, we systematically compared genesets involved in regulating the lifespan of Saccharomyces cerevisiae (a powerful model organism to study the cellular aging of humans) and those with expression changes under rapamycin treatment. Among the functionally uncharacterized genes in the overlap set, YBR238C stood out as the only one downregulated by rapamycin and with an increased chronological and replicative lifespan upon deletion. We show that YBR238C and its paralog RMD9 oppositely affect mitochondria and aging. YBR238C deletion increases the cellular lifespan by enhancing mitochondrial function. Its overexpression accelerates cellular aging via mitochondrial dysfunction. We find that the phenotypic effect of YBR238C is largely explained by HAP4- and RMD9-dependent mechanisms. Furthermore, we find that genetic- or chemical-based induction of mitochondrial dysfunction increases TORC1 (Target of Rapamycin Complex 1) activity that, subsequently, accelerates cellular aging. Notably, TORC1 inhibition by rapamycin (or deletion of YBR238C) improves the shortened lifespan under these mitochondrial dysfunction conditions in yeast and human cells. The growth of mutant cells (a proxy of TORC1 activity) with enhanced mitochondrial function is sensitive to rapamycin whereas the growth of defective mitochondrial mutants is largely resistant to rapamycin compared to wild type. Our findings demonstrate a feedback loop between TORC1 and mitochondria (the TORC1–MItochondria–TORC1 (TOMITO) signaling process) that regulates cellular aging processes. Hereby, YBR238C is an effector of TORC1 modulating mitochondrial function.